Skip to main content

Table 1 Summary of drugs tested for in vitro and in vivo potentiation in combination with electroporation pulses

From: Electrochemotherapy: from the drawing board into medical practice

Drug tested In vitro potentiation In vivo potentiation
Bleomycin Yes; 100–5000-fold [1, 17, 18, 2628] Yes
Cisplatin Yes; 1.8–12.2-fold [17, 18, 28, 29] Yes [2830]
Calcium Yes; more hundred-fold [31, 32] Yes [31]
Netropsin Yes; 200-fold [1]
Carboplatin Yes; 1.6–13-fold [17, 18, 27, 29]
2-N-methyl-9-hydroxy-ellipticinium (NMHE) Yes; 4-fold [1]
Vincristine Yes; 1.3–3.4-fold [18]
ActiNomycin D Yes; 2–3-fold [1]
Cytarabine Yes; 2-fold [18]
Oxaliplatin Yes [29]
Platinum (II) complex 3P-SK Yes [29] Yes [29]
Platinum (II) complex PtAMP Yes [29]
Mitomycin C Yes but low; 1.3–1.4-fold [18, 33]
Vinblastine Yes but low; 1.1–1.3-fold [18]
5-fluorouracil No or low; 1.25-fold [18, 26]
Paclitaxel No or low; 1.3-fold [17, 18]
Doxorubicin No or low; 0.67–2-fold [17, 18]
Nimustine hydrochloride (ACNU) No [27]
Methotrexate No [1]
9-OH-ellipticine No [1]
Didemnin B No [1]
Melphalan No [1]
Mithramycin No [1]
Taxotere No [1]
DauNorubicin No [17]
Adriamycin No [32] No [28]
Etoposide No or ND [17, 18, 27]
Ancitabine ND [18]
Gemcitabine ND [18]
  1. ND drug was tested but the potentiation could Not be determined due to methodological limitations.
  2. – Not tested.